SleepScore and IFF collaborate to innovate better sleep products

By Nikita Chaurasia  Date: 2020-01-07

SleepScore and IFF collaborate to innovate better sleep products

SleepScore Labs, a US-based data-backed sleep solution offering company, reportedly announced a new strategic collaboration with IFF (International Flavors & Fragrances) to validate and create products innovated to help people live healthier lives using improved sleep. IFF is a renowned American company involved in manufacturing fragrances and flavors and cosmetic actives.

IFF’s Divisional CEO, Scent, Nicolas Mirzayantz stated that this collaboration is a strategic decision taken by the company to extend its footprint in the “beyond sensorial” industry. Together both companies would build on SleepScore’s best-in-class data capture and analysis capability and IFF’s Consumer and Sensory Science knowledge to offer validated scent-based sleep solutions for customers.

From the beginning of 2018, both the organizations have been partnering for a sleep fragrance. They have also gathered more than 6,500 nights of sleep data together. As the primary step of this partnership, SleepScore clinically studied an initial scent creation model, a pillow spray. This pillow spray was designed particularly to aid healthy sleep.

Outcomes of the double-blind, counter-balanced and placebo-controlled trial discovered that the scent offered the greatest advantage to healthy sleepers. Also, objective sleep measurement discovered that participants spent 26% lesser time being awake at night once they fell asleep after using the scent. These scientifically proven outcomes support the creation of novel product categories built for customers to have better sleep.

To gain insights, SleepScore Labs scientists performed a trial to assess the effectiveness of a pillow spray for 800 nights. The company took both objective sleep measures and self-reported data each night. Objective sleep measures are crucial to finding the potential value that scented products have on the users’ sleep. These measures were obtained using SleepScore technology backed by ResMed, a revolutionary authority for innovative medical devices that enable people to lead higher-quality and healthier lives.

SleepScore Labs CEO, Colin Lawlor stated that the company’s work with IFF is another example of how the company is the only one in the sleep space that is capable of incorporating data, actionable insights and measurement to allow organizations to further strengthen their wellness and health offerings.

 

Source credit: https://www.citizentribune.com/news/business/sleepscore-labs-and-international-flavors-fragrances-innovate-in-groundbreaking-sleep/article_0452bbd3-4c60-5053-82cd-3f0517ad0189.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...